Skip to main content
. 2020 Apr 1;8(1):e000166. doi: 10.1136/jitc-2019-000166

Table 2.

Mutation load, putative and identified immunogenic neoantigens in melanoma cell lines

Cell line
code
(response)
InDELs Substitutions
(total)
Non-synonymous substitutions Tested peptides Recognized T cell epitopes Reference
MEL 04.01
(SD > 6 months)
3 487 320 226 SLP EML1(R64W)
SEPT2 (R300C)
CAD(R1854Q)3
26
MEL 05.18
(CR)
1 1243 811 501 SLP RPS12(V104I)
ZC3H18(G269R)
TNIK(S502F)
KIAA0020(P451L) ribosomal protein RPL28(S76F)
39
39
39
26
26
MEL 08.11
(PR)
0 442 306 207 SLP TP53 (L194F) This article
MEL 09.10
(SD > 6 months)
2 952 635 106 SSP CLPTM1 (P485L)
ETV5 (P465S)
NIPAL2 (L95P)
TNFRSF12A (I197N)
MPDU1 (P213L)
ERRFI1 (L338F)
ZNF532 (S263L)
This article
This article
This article
This article
This article
This article
This article

The mutation load, defined by number of insertions and deletions (InDELs) and the total number of substitutions is depicted. The number of synthetic long (SLP) or short (SSP) peptides comprise all the non-synonymous substitutions which have a detectable RNA expression (>0) in the tumor sample, excluding those that introduce a premature stop codon.

CR, complete response; PR, partial response; SD, stable disease.